FDA gives priority review to Cogent’s GIST drug combination: full analysis
Cogent Biosciences has cleared an important regulatory step for its GIST program: the FDA accepted the company’s NDA for bezuclastinib in combination with sunitinib and granted Priority Review for adults with GIST previously treated with imatinib. The filing carries a Prescription Drug User Fee Act, or PDUFA, target action date of November 30, 2026, shortening the FDA’s review goal from the standard 10 months to 6 months. (investors.cogentbio.com)
The application builds on a strategy Cogent has been advancing for months. In January 2026, the company said FDA agreed to review the application through the Real-Time Oncology Review program, an Oncology Center of Excellence pathway meant to streamline review of certain oncology submissions. In April 2026, Cogent announced it had completed the NDA submission, following an earlier Breakthrough Therapy designation for the regimen in GIST. (investors.cogentbio.com)
The core data come from the global, randomized phase 3 PEAK study in patients with locally advanced, metastatic, or unresectable GIST whose disease had progressed on, or who were intolerant to, imatinib. According to Cogent, at a September 30, 2025 cutoff, the combination reduced the risk of progression or death by 50% compared with sunitinib alone, with median progression-free survival of 16.5 months versus 9.2 months. Outside coverage of the upcoming ASCO presentation also reports that 413 patients were randomized in the trial, underscoring that this was a sizable registrational study in a relatively uncommon tumor type. (investors.cogentbio.com)
The biological rationale is straightforward and has helped the program stand out. ASCO materials describe bezuclastinib as a type I KIT inhibitor with activity against KIT activation loop resistance mutations, while sunitinib has complementary activity against ATP-binding pocket resistance mutations. In other words, the combination is designed to cover different resistance pathways that emerge in GIST after imatinib, rather than relying on a single kinase inhibitor to do all the work. (ascopubs.org)
Independent reaction appears measured but optimistic. Coverage ahead of the ASCO presentation has framed PEAK as a study that could usher in a new second-line therapy for GIST, and OncLive noted Cogent is positioning the regimen for a possible 2026 launch if approved. That said, broader expert commentary is still limited ahead of the full data presentation, so the field will likely wait for the ASCO readout to scrutinize subgroup performance, tolerability, dose intensity, and durability before treating the result as practice-changing. (ecancer.org)
Why it matters: For veterinary professionals, this is mainly relevant as a window into where targeted oncology is heading. Human GIST care has historically followed a sequence of TKIs, with sunitinib entrenched as a standard second-line therapy after imatinib. A successful approval here would validate a more mutation-aware combination approach to KIT-driven cancers, a concept with clear comparative oncology interest even if the immediate commercial impact is outside animal health. It also shows how FDA tools such as Breakthrough Therapy designation, RTOR, and Priority Review can compress timelines when a company brings randomized phase 3 data in an area of unmet need. (cancer.gov)
There’s also a competitive backdrop worth noting. Other companies are still trying to improve on second-line GIST treatment, including trials comparing newer agents against sunitinib, which suggests the space remains active despite sunitinib’s long-standing place in care. Cogent, for its part, has said it also expects to start a phase 2 study in mid-2026 evaluating bezuclastinib plus sunitinib in first-line GIST patients with exon 9 mutations. That points to a broader lifecycle strategy beyond the current post-imatinib setting. (gsk.com)
What to watch: The next near-term catalyst is the full PEAK presentation at ASCO on May 30, 2026, followed by any updated safety and subgroup analysis that could shape clinician confidence. After that, attention will shift to the FDA’s November 30, 2026 decision, potential label details, and whether Cogent can move the combination earlier in treatment if its planned first-line study gets underway on schedule. (investors.cogentbio.com)